New Zealand markets close in 3 hours 27 minutes

Roivant Sciences Ltd. (ROIV)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1100+0.1600 (+5.42%)
At close: 04:00PM EDT
3.2600 +0.15 (+4.82%)
After hours: 06:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9500
Open2.9700
Bid3.0700 x 2200
Ask3.6400 x 1300
Day's range2.9700 - 3.1100
52-week range2.5200 - 16.7600
Volume464,602
Avg. volume868,209
Market cap2.191B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.5170
Earnings date15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.29
  • GlobeNewswire

    Roivant to Participate in September Investor Events

    Three healthcare investor conferences in September across Boston, New York and LondonRoivant Investor Day will take place virtually on September 28th starting at 11 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences and hold an investor day in September: Citi BioPharma Conference in Boston on Wednesday, September 7thH.C. Wainwright Global Investment Conference

  • Simply Wall St.

    Time To Worry? Analysts Are Downgrading Their Roivant Sciences Ltd. (NASDAQ:ROIV) Outlook

    The latest analyst coverage could presage a bad day for Roivant Sciences Ltd. ( NASDAQ:ROIV ), with the analysts making...

  • GlobeNewswire

    Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

    Amy Mahery Amy Mahery Early launch data for VTAMA® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical novel chemical entity for plaque psoriasis in 25 yearsThe Journal of the American Academy of Dermatology (JAAD) published the Phase 3 long-term extension study highlighting the unique mechanism for the remittive effect of VTAMA showing mean duration off-therapy for patients achi